Novo Nordisk: Oral Weight-Loss To The Rescue

Novo Nordisk’s oral Wegovy wins FDA approval, outperforming rivals in weight loss. Discover why NVO stock is undervalued now.

Stock Market Today, Dec. 26: Nvidia Rises on $20 Billion Groq Licensing Deal

On Dec. 26, 2025, a $20 billion Groq licensing pact sharpened Nvidia's role at the center of AI data center build‑outs.

Stock Market Today, Dec. 26: S&P Notches New High As Investors Digest Nvidia-Groq Deal

While today's final performance was muted, the S&P 500 set a new record in intraday trading as investors returned from the ...
24/7 Wall St.

Stock Market Live December 26: Nvidia to Buy Groq, S&P 500 (VOO) Flat After Christmas

Live Updates Get The Best Vanguard S&P 500 ETF Live Earnings Coverage Like This Every Quarter Get earnings reminders, our top ...

GoGold: A Good Value Even With More Conservative Metal Prices

GoGold Resources is a top buy for silver investors, with strong assets, cash flow, and upside. Click here to read my latest ...

Wegovy Pill Approval Sends Novo Nordisk Stock Soaring. What It Means for Eli Lilly.

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss ...